Yarrow Bioscience, Inc. operates as a clinical-stage biotechnology company that engages in developing transformative therapies for autoimmune thyroid diseases. The company's candidate, YB-101, is a humanized monoclonal antibody targeting the thyroid-stimulating hormone receptor (TSHR) for the treatment of Graves' disease and thyroid eye disease. The company was incorporated in 2025 and is based in New York, New York.
Frequently asked questions
What sector does YARW (YARW) operate in?
YARW belongs to the Other sector and operates in the Biotechnology industry.
What is YARW (YARW) current stock price?
As of the latest data, YARW stock price is $20.00, with a previous close of $19.27. YARW gained $0.73 in the last trading session, representing a 3.79% increase.
What is YARW (YARW) current market capitalization?
YARW market cap is approximately 53.39 million.
What is YARW (YARW) EBITDA?
YARW EBITDA (Earnings Before Interest, Taxes, Depreciation, and Amortization) is -2.90 million.
Does YARW (YARW) pay dividends?
No. YARW does not pay a dividend.
When is YARW (YARW) next earnings report?
YARW is expected to release its next earnings report on September 30, 2026.
What is YARW (YARW) beta (volatility) score?
YARW has a beta of 2.068, indicating very high volatility compared to the market.